In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...

Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-a | A ...

Merck (MRK) stock is in focus as its blockbuster drug Keytruda as part of a combo regimen hits a secondary goal in a Phase 3 ...

Welcome to The Pharma Letter’s real-time coverage of the 2025 European Society of Medical Oncology (ESMO) Congress, taking ...

Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with ...

The company is studying the mRNA tumor-associated antigen vaccine as a monotherapy and in combination with Keytruda.

Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License ...

The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with ...

MRK's Keytruda remains its dominant growth engine and is expected to have boosted its top line in the third quarter.

Bristol Myers Squibb Co said on Wednesday its cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease versus chemotherapy alone in a late-stage ...

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the ...